Cannabis-derived MS treatment disappoints in Phase III trial
Initial results from Jazz Pharmaceuticals’ Phase III study on Sativex (JZP378) for the treatment of multiple sclerosis failed to achieve the primary endpoint of an improvement in muscle tone.